The deal expands the pharmaceutical company’s portfolio of cancer drugs.
Source link
Tags: acquisitions, Acquisitions/Mergers, Acquisitions/Mergers/Shareholdings, Biopharmaceuticals, Biotechnology Services, BMY, Bristol Myers Squibb, C&E Industry News Filter, Cancer, Cancer Drugs, Content Types, corporate, Corporate Actions, corporate strategy, Corporate Strategy/Planning, Corporate/Industrial News, Factiva Filters, general news, Health, healthcare, Healthcare/Life Sciences, industrial news, life sciences, Medical Conditions, medications, mergers, Mirati Therapeutics, MRTX, Ownership Changes, Pharmaceuticals, Physical Asset Transactions, planning, political, Political/General News, shareholdings, specialized drugs, Specialized Drugs/Medications, SYND, WSJ-PRO-WSJ.com
